Skin Cancer: Mistake to avoid during the winter months to prevent the disease - expert
SKIN cancer is one of the most common cancers worldwide, with 147,000 new cases of non-melanoma skin cancer diagnosed in the UK every year. Express.co.uk spoke to a skin expert about a mistake to avoid that could lead to this condition even in winter. (Source: Daily Express - Health)
Source: Daily Express - Health - December 4, 2021 Category: Consumer Health News Source Type: news

FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma  
On December 3,2021, the Food and Drug Administration  approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete resection. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 3, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Differences in Response to Immunotherapy in Men vs Women Differences in Response to Immunotherapy in Men vs Women
Women with advanced melanoma had a twofold increase in mortality risk, compared with male counterparts, when treated with combination checkpoint inhibition.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 2, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

University of Hawaii at Manoa Cancer Center study uses AI to detect skin cancer
The University of Hawaii Cancer Center has seen significant progression in innovation in the last 50 years, most recently in a study that has identified new ways to detect skin cancer using artificial intelligence, or AI. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 29, 2021 Category: Pharmaceuticals Authors: Kelsey Kukaua Source Type: news

Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost Triplet Regimen Boosts Survival in Metastatic Melanoma, but at a Cost
For patients with metastatic melanoma, triplet therapy with atezolizumab and vemurafenib plus cobimetinib provides significant survival benefits, but the regimen may not be cost-effective, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 25, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

The Time of Day of Immunotherapy Infusions Affects Survival The Time of Day of Immunotherapy Infusions Affects Survival
A new study reveals that giving immunotherapy infusions earlier in the day leads to better overall survival for patients with advanced melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Go to the toilet in the middle of the night? It could be a sign of cancer
PROSTATE CANCER is the second most common cancer for men, only behind skin cancer. However, many people aren't aware of what the symptoms of prostate cancer are - including the symptoms in your urine. (Source: Daily Express - Health)
Source: Daily Express - Health - November 21, 2021 Category: Consumer Health News Source Type: news

Young woman devastated as 'cute' heart-shaped freckle diagnosed as 'aggressive' skin cancer
Kayla Mailer, 32, from Portland, Oregon, went to see her doctor when the 'super-cute' freckle on her cheek started changing color and shape. She was devastated to learn it was cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - November 18, 2021 Category: Consumer Health News Source Type: news

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

UCLA scientists make strides toward an ‘off-the-shelf’ immune cell therapy for cancer
Immunotherapies, which harness the body ’s natural defenses to combat disease, have revolutionized the treatment of aggressive and deadly cancers. But often, these therapies — especially those based on immune cells — must be tailored to the individual patient, costing valuable time and pushing their price into the hundreds of thousa nds of dollars.Now, in a study published in the journal Cell Reports Medicine, UCLA researchers report a critical step forward in the development of an “off-the-shelf” cancer immunotherapy using rare but powerful immune cells that could potentially be produced...
Source: UCLA Newsroom: Health Sciences - November 16, 2021 Category: Universities & Medical Training Source Type: news

T2DM and Markers of Cutaneous Melanoma Aggressiveness T2DM and Markers of Cutaneous Melanoma Aggressiveness
This study investigated a possible relationship between type 2 diabetes mellitus and an increased incidence and/or aggressiveness of melanoma, with or without metformin therapy.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 10, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Skin of Color Underrepresented in Datasets Used by AI to Identify Skin Cancer Skin of Color Underrepresented in Datasets Used by AI to Identify Skin Cancer
Data on ethnicity and Fitzpatrick skin type were rarely available in open-access databases used by AI to identify skin cancer, and very few images were of individuals with darker skin types.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 10, 2021 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

AI skin cancer diagnoses risk being less accurate for dark skin – study
Research finds few image databases available to develop technology contain details on ethnicity or skin typeAI systems being developed to diagnose skin cancer run the risk of being less accurate for people with dark skin, research suggests.The potential of AIhas led to developments in healthcare, with some studies suggesting image recognition technology based on machine learning algorithms can classify skin cancersas successfully as human experts.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 9, 2021 Category: Science Authors: Nicola Davis Science correspondent Tags: Skin cancer Health Science Artificial intelligence (AI) Technology Race NHS Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Skin Checks Reduce All-Cause but Not Melanoma-Specific Deaths Skin Checks Reduce All-Cause but Not Melanoma-Specific Deaths
The findings are based on a study conducted in Australia, which assessed melanoma-specific and all-cause mortality associated with melanoma identified through routine skin checks.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 3, 2021 Category: Internal Medicine Tags: Dermatology News Source Type: news

All - Cause Mortality Lower for Melanomas ID ’ d in Routine Skin Checks
After adjustment for prognostic factors, no association seen between detection by routine skin check and melanoma - specific mortality (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 3, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

PET tracer proves effective for assessing immunotherapy
PET imaging can show whether patients with melanoma or non-small cell lung cance...Read more on AuntMinnie.comRelated Reading: U.S. cancer care financial burden hit $21B in 2019 New PET radiotracer more effective at detecting cancer PET tracer predicts response to immunotherapy AI can lend a hand in diagnosis, prognosis of oral SCC PET/CT shows promise predicting outcomes in head, neck cancer (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2021 Category: Radiology Source Type: news

Study Supports Opdivo as Second-Line Mesothelioma Treatment
When the effectiveness of first-line chemotherapy fails and malignant mesothelioma returns, more patients could soon turn with confidence to a proven, second-line treatment. The first phase III, placebo-controlled, double-blind clinical trial studying the safety and efficacy of Opdivo, the immunotherapy drug known generically as nivolumab, has raised the level of confidence in this option for patients with relapsed disease. “The evidence is robust, the survival significant,” Dr. Dean Fennell, chair of Thoracic Medical Oncology, University of Leicester and University Hospitals in the United Kingdom, told T...
Source: Asbestos and Mesothelioma News - November 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

A Review and Call for More Research Into Nodular Melanoma A Review and Call for More Research Into Nodular Melanoma
This paper highlights the distinct characteristics of nodular melanoma, an aggressive subtype associated with poor survival.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 27, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Fighter pilots are more likely to get testicular, prostate or skin cancer, study finds
An Air Force study finds that fighter pilots are at an increased risk of developing certain cancers when compared to other airmen, though the reason why can not yet be determined. (Source: the Mail online | Health)
Source: the Mail online | Health - October 25, 2021 Category: Consumer Health News Source Type: news

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Mystery of the environmental triggers for cancer deepens
Study shows that our knowledge of why tumours form is still inadequateScientists will have to rethink howenvironmental triggers allow tumours to form and develop, one of Britain ’s leading cancer experts warned last week. Michael Stratton, director of the Wellcome Sanger Institute, said recent results from an international cancer research study – which aimed to pinpoint environmental triggers involved in oeosophageal cancer – indicated current scientific understanding of tumour formation was inadequate.The research – on a type known as oesophageal squamous cell carcinoma – was aimed at uncover...
Source: Guardian Unlimited Science - October 24, 2021 Category: Science Authors: Robin McKie Tags: Cancer research Medical research UK news Science Source Type: news

Fecal Transplants May Improve Resistance to Melanoma Therapy Fecal Transplants May Improve Resistance to Melanoma Therapy
' The big question...is why and how does FMT work, and how can we make the response better?'asked Dr Teri Greiling of Oregon Health& Science University.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 21, 2021 Category: Gastroenterology Tags: Dermatology News Source Type: news

Skin cancer: The body part you 'routinely cannot see' symptoms – 'extra care' needed
SKIN cancer is a common form of cancer in the UK, and more than one in four skin cancer cases are diagnosed in people under 50, "which is unusually early compared with most other types of cancer", according to the NHS. (Source: Daily Express - Health)
Source: Daily Express - Health - October 16, 2021 Category: Consumer Health News Source Type: news

Consumer Health: Are you due for a mammogram?
National Mammography Day will be observed on Friday, Oct. 15, which makes this a good time to check if you're due for a mammogram. A mammogram is an X-ray image of your breasts that is used to screen for breast cancer. Mammograms play a key role in early breast cancer detection and help decrease breast cancer deaths. Breast cancer will affect 1 in 8 women, according to the American Cancer Society. After skin cancer, breast cancer is the most common… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 15, 2021 Category: Databases & Libraries Source Type: news

Skin Cancer App Fails to Identify Rare, Aggressive Cancers
Sensitivity and specificity for detecting Merkel cell carcinoma and amelanotic melanoma was 79.4 and 37.7 percent, respectively (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 14, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Pathology, Conference News, Source Type: news

Interventions for Basal Cell Carcinoma Interventions for Basal Cell Carcinoma
Which are the most effective interventions for primary basal cell carcinoma? This systemic review examined the current evidence for both surgical and non-surgical treatments.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Can Skin Cancer Kill You
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 12, 2021 Category: General Medicine Source Type: news

HEALTH NOTES: Smartphone apps claiming to test for skin cancer may lead to avoidable deaths
Smartphone apps that test for skin cancer are inaccurate and could lead to avoidable deaths, according to scientists from Queen Mary University of London. (Source: the Mail online | Health)
Source: the Mail online | Health - October 9, 2021 Category: Consumer Health News Source Type: news

Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associa...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Surgery Choice for Rare Skin Cancer Differs by Racial Group Surgery Choice for Rare Skin Cancer Differs by Racial Group
"Because MMS [Mohs micrographic surgery] is associated with significantly improved outcomes, identifying at-risk patient populations and barriers to accessing MMS is essential," the researchers write.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2021 Category: Consumer Health News Tags: Dermatology News Source Type: news

New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque p...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Is Ocular Melanoma Same as Uveal Melanoma?
Title: Is Ocular Melanoma Same as Uveal Melanoma?Category: Diseases and ConditionsCreated: 10/4/2021 12:00:00 AMLast Editorial Review: 10/4/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 4, 2021 Category: Cancer & Oncology Source Type: news

Consumer Health: Metastatic breast cancer
October is Breast Cancer Awareness Month, which makes this a good time to learn more about metastatic breast cancer. Breast cancer will affect 1 in 8 women, according to the American Cancer Society. After skin cancer, breast cancer is the most common cancer diagnosed in women in the U.S. Metastatic breast cancer is cancer that originated in the breasts and has spread to other parts of the body. It may be apparent at the time of initial… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 4, 2021 Category: Databases & Libraries Source Type: news

Young woman, 25, reveals the terrifying moment she was diagnosed with skin cancer
A young woman who has been battling with an incurable autoimmune disease since the age of 17 has spoken of the terrifying moment she was diagnosed with skin cancer at 25. (Source: the Mail online | Health)
Source: the Mail online | Health - October 1, 2021 Category: Consumer Health News Source Type: news

Tanning addict who used sunbeds to clear up her eczema gets skin cancer 
Daniella Bolton, a sales administrator from Edinburgh, was diagnosed with skin cancer after using sunbeds twice a week for up to 12 minutes at a time over two years. (Source: the Mail online | Health)
Source: the Mail online | Health - September 29, 2021 Category: Consumer Health News Source Type: news

Lithuanian Researchers Develop Novel Noninvasive Method for Diagnosing Melanoma That Has Greater than 90% Accuracy
Computer-aided diagnostic system combines optical dermatoscopy, spectrophotometry and high-frequency ultrasound imaging techniques to differentiate malignant lesions from benign moles Detecting skin cancer via the use of skin biopsies is the bread and butter of many dermatopathology practices. But new technologies that can instantly detect and distinguish different types of skin malignancies may result in a […] The post Lithuanian Researchers Develop Novel Noninvasive Method for Diagnosing Melanoma That Has Greater than 90% Accuracy appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - September 29, 2021 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: International Laboratory News Laboratory Instruments & Laboratory Equipment Laboratory Pathology Laboratory Testing Precision Medicine Abraham Katzir PhD anatomic pathology clinical laboratory clinical pathology Dark Daily dark intelli Source Type: news

A Clinical and Biological Review of Keratoacanthoma A Clinical and Biological Review of Keratoacanthoma
Can keratoacanthomas be differentiated from cutaneous squamous cell carcinoma? This review compares the pathophysiology and clinical characteristics of the two, suggesting they are distinct entities.The British Journal of Dermatology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2021 Category: Surgery Tags: Dermatology Journal Article Source Type: news

Penn Medicine, Wistar Institute get $11.7M NCI grant to develop potential melanoma treatments
The National Cancer Institute (NCI) awarded Penn Medicine and The Wistar Institute $11.7 million to support melanoma research. The five-year award from the NCI's Specialized Programs of Research Excellence will be used to fund three new melanoma research projects. The projects will seek to translate laboratory discoveries made in the Perelman School of Medicine at the University of Pennsylvania and at The Wistar Institu te, both in West Philadelphia, into new therapeutics to treat skins cancers. Melanoma… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - September 24, 2021 Category: American Health Authors: John George Source Type: news

Survival Up With Tebentafusp in Metastatic Uveal Melanoma
Overall survival longer with tebentafusp for HLA*02:01 - positive patients with previously untreated metastatic uveal melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 23, 2021 Category: Cancer & Oncology Tags: Oncology, Ophthalmology, Pharmacy, Journal, Source Type: news

The Association Between Citrus Consumption and Melanoma Risk The Association Between Citrus Consumption and Melanoma Risk
Psoralen, a known photocarcinogen, is abundant in citrus products. Might consumption of citrus be associated with an increased risk of melanoma?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 22, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Adjuvant Pembrolizumab Cuts Recurrence in Stage II Melanoma
Compared with placebo, pembrolizumab prolonged regression - free survival in resected high - risk stage IIB and IIC melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 20, 2021 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Watchful Waiting in BCC: Which Patients Can Benefit? Watchful Waiting in BCC: Which Patients Can Benefit?
Some patients with basal cell carcinoma (BCC) may not need treatment. New data reveal who those patients likely are.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 20, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Salty Diet Helps Gut Bugs Fight Cancer in Mice: Study
A high-salt diet suppressed the growth of tumors in a mouse model of melanoma, apparently because of an interplay between the gut microbiome and natural killer cells. (Source: The Scientist)
Source: The Scientist - September 20, 2021 Category: Science Tags: News & Opinion Source Type: news

Dermatologist tackles sun safety while growing her business via QVC
As a mother, Erum Ilyas worried about her children ’s sun safety. Was their sunscreen washing off in the pool? Were their clothes properly protecting them? Did they slather on SPF before heading to the beach with friends? As a doctor, those concerns extended to her patients. The most common cancer in the U.S., an estimated one in five Americans will develop skin cancer in their lifetime, according to the American Academy of Dermatology Association. Seeing the frustrations her patients had with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2021 Category: Biotechnology Authors: Lisa Dukart Source Type: news

Adjuvant Pembro Success in Early Melanoma Raises Questions Adjuvant Pembro Success in Early Melanoma Raises Questions
Adjuvant pembrolizumab significantly improved recurrence-free survival in stage 2B/C melanoma in KEYNOTE 716, but which patients benefit most and what does this mean for treatment down the line?Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

How a plant virus could protect and save your lungs from metastatic cancer
Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at bay from the lungs. The treatment not only slowed tumor growth in the lungs of mice with either metastatic breast cancer or melanoma, it also prevented or drastically minimized the spread of these cancers to the lungs of healthy mice that were challenged with the disease. (Source: World Pharma News)
Source: World Pharma News - September 14, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news